Log In
BCIQ
Print this Print this
 

epratuzumab-Rap

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionHumanized mAb targeting CD22 fused to an amphibian RNase using dock and lock (DNL) conjugation technology
Molecular Target CD22
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today